PT-141 (Bremelanotide)
FDA APPROVED · RXMelanocortin receptor agonist
Also known as: Bremelanotide, Vyleesi
FDA approved and prescription only. Sold as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 3 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 2 cited sources. Includes primary / regulatory sources
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven in human trials: a modest but real increase in sexual desire in premenopausal women with HSDD, enough for FDA approval. Nausea is very common. Male ED use is off-label and less well established.
What it is
Activates melanocortin receptors in the brain, influencing sexual desire and arousal centrally rather than through blood flow.
What the research says
Approved based on human trials showing a modest improvement over placebo.
Studied historically but not the approved indication.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where PT-141 (Bremelanotide) is the intervention being tested.
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
FDA recalls & enforcement
No FDA recalls are on record for PT-141 (Bremelanotide).
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Nausea is very common (around 40% at higher trial doses).
- Can cause a temporary, mild rise in blood pressure; avoided in uncontrolled hypertension or cardiovascular disease.
- Flushing and headache reported.
Doses reported in studies & protocols
Approved on-demand dosing is set by the label and prescriber. This is not a recommendation.
Purity reality
Pharmacy Vyleesi is verified; gray-market PT-141 is not.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
- Bremelanotide overview (ScienceDirect, pharmacology)
- King et al., melanocortins & penile erection, 2007 (PMC/NIH)
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.